Buynomics GmbH, founded in 2018 and based in Cologne, Germany, specializes in developing and distributing pricing machine software and innovative AI solutions. The company creates Virtual Customers that simulate the buying behavior of real consumers, allowing businesses in the consumer-packaged goods and telecommunications sectors to gain accurate insights into customer preferences. By leveraging big data analytics and computer simulations, Buynomics enables its clients to make informed decisions regarding pricing, promotions, product offerings, and trade terms. This holistic approach links critical revenue levers and provides actionable recommendations, facilitating data-driven commercial strategies that promote profitability and sustainability.
Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.
Kadoa is an AI-powered no-code platform that allows anyone to build complex data workflows effortlessly.
Oplit is a production planning platform that provides software and support to help industrials boost operations profitability.
Somagenetix is a biotechnology company focused on developing innovative gene therapies for phagocyte-related illnesses, particularly targeting severe inherited immune diseases, immunodeficiency, neurodegeneration, and cancer with brain metastases. The company specializes in discovering and developing stem cells from bone marrow and utilizing lentiviral vectors to deliver therapeutic genes. This approach aims to correct the underlying genetic defects in patients by transplanting gene-corrected cells back into the body, ultimately providing a potential cure for various monogenic disorders. With a commitment to advancing the field of gene therapy, Somagenetix aims to lead in creating first-in-class treatments that address significant medical needs.
Almer Technologies is a startup focused on creating compact and lightweight augmented reality (AR) glasses aimed at enhancing communication for frontline workers in industrial settings. The company offers a comprehensive AR solution that includes both hardware and software, partnering with industry leaders to integrate advanced functionalities. By equipping frontline workers with these AR glasses, Almer enables them to access expertise directly in their field of view, facilitating remote problem-solving and minimizing downtime. This innovative approach streamlines communication and improves operational efficiency in technical industries.
XO Life operates an online platform focused on digital patient monitoring and engagement. The platform is designed to enhance patient education and support by offering real-world insights into patient preferences and treatment outcomes. It facilitates communication between patients and pharmaceutical companies, allowing for the exchange of feedback and information that improves adherence to treatments. By providing services such as patient companionship and insights into various drugs and diseases, XO Life aims to foster better relationships between patients and healthcare providers, ultimately contributing to improved patient outcomes and loyalty.
Flowit provides an end-to-end approach that makes modern, digital HR a breeze allowing organizations to streamline their processes.
iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.
Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.
LeaseTeq is a FinTech company focused on transforming the automotive leasing experience through innovative digital solutions. Established in 2021, it aims to simplify the leasing process by offering a streamlined platform that enables both individuals and businesses to lease vehicles efficiently. The company's services prioritize convenience and speed, featuring a paperless application process that enhances environmental sustainability while ensuring discretion and security for users. Through its technology-driven approach, LeaseTeq seeks to make leasing more accessible and user-friendly.
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Oculis is a global biopharmaceutical company focused on advancing eye care and preserving vision through innovative drug delivery solutions. The company's unique platform enables effective drug absorption in both the anterior and posterior segments of the eye, allowing for the treatment of conditions such as diabetic macular edema (DME) with a simple topical application, thus eliminating the need for invasive procedures. Oculis is developing several therapeutic candidates, including OCS-01, a topical treatment for DME; OCS-02, aimed at addressing dry eye disease; and OCS-05, which targets acute optic neuritis and other neuro-ophthalmic disorders. This novel approach not only facilitates treatment for posterior eye diseases but also reduces the required frequency of applications for anterior conditions compared to traditional eye drops.
Acodis is a developer of document digitalization software that transforms various types of documents into structured data quickly and efficiently. Utilizing artificial intelligence, Acodis' machine learning engine can read and comprehend documents similarly to humans, allowing businesses to automate data extraction across multiple formats and layouts. This capability significantly reduces the time and effort spent on manual data entry, enhances accuracy, and improves overall productivity. The software supports documents in any language and integrates seamlessly with existing systems, enabling users to export data via API to enhance their ERP, CRM, or RPA systems. By streamlining document processing, Acodis empowers organizations to derive valuable insights and optimize their business operations.
Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.
Skribble is a platform for electronic signatures that presupposes the identification of the signatures. The platform provides the legally suitable electronic signature for every type of contract even if the law requires the same legal weight as a handwritten signature. It allows signing documents electronically with just a few clicks legally binding in accordance with Swiss & EU law. Skribble was founded in 2018 and is headquartered in Zurich, Switzerland.
Morgen lets you manage and optimize your time from a single app. As the demands on our time have grown increasingly complex, so too has our time management - multiple calendars for work and life, to do apps, project management tools, and schedulers. All those tools are fragmenting the way we manage time rather than simplifying it. Morgen integrates with all calendars and your go-to task and project management tools. It additionally has a native scheduling tool. This lets Morgen users plan, organize and optimize their time all from one place.
Ninox empowers line-of-business teams to automate backoffice workflows without the help of a developer. With this No-Code approach we help more than 2.800 companies across all industries to digitize business proceses. The market for no- and low-code application platforms grows rapdily and is expected to reach $27B in 2022. Leading vendors are Mendix, Outsystems and Appian. Though they manage to reduce time and effort to build custom business applications by factor 10 to 15, established products require extensive training and are sold at a price point that makes their introduction a strategic decision. Ninox is different: Combinig the smooth onboarding of modern productivity apps with the high flexibility of application platforms, we level the ground for a much broader adoption.
Picterra SA is a company that operates an online platform designed to create and automate artificial intelligence (AI) workflows for object detection in geospatial data. Founded in 2016 and headquartered in Écublens, Switzerland, Picterra combines AI with satellite, drone, and aerial imagery to provide optimized geo-information. This platform enables users to monitor and anticipate changes in their environments, delivering valuable insights across various industries, including aerial imaging, mapping, financial services, insurance, journalism, precision agriculture, real estate, utilities, infrastructure, and the public sector. By leveraging cloud-based machine learning capabilities, Picterra empowers clients to efficiently extract and analyze earth observation data, facilitating informed decision-making.
Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Acodis is a developer of document digitalization software that transforms various types of documents into structured data quickly and efficiently. Utilizing artificial intelligence, Acodis' machine learning engine can read and comprehend documents similarly to humans, allowing businesses to automate data extraction across multiple formats and layouts. This capability significantly reduces the time and effort spent on manual data entry, enhances accuracy, and improves overall productivity. The software supports documents in any language and integrates seamlessly with existing systems, enabling users to export data via API to enhance their ERP, CRM, or RPA systems. By streamlining document processing, Acodis empowers organizations to derive valuable insights and optimize their business operations.
Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.
Oculis is a global biopharmaceutical company focused on advancing eye care and preserving vision through innovative drug delivery solutions. The company's unique platform enables effective drug absorption in both the anterior and posterior segments of the eye, allowing for the treatment of conditions such as diabetic macular edema (DME) with a simple topical application, thus eliminating the need for invasive procedures. Oculis is developing several therapeutic candidates, including OCS-01, a topical treatment for DME; OCS-02, aimed at addressing dry eye disease; and OCS-05, which targets acute optic neuritis and other neuro-ophthalmic disorders. This novel approach not only facilitates treatment for posterior eye diseases but also reduces the required frequency of applications for anterior conditions compared to traditional eye drops.
CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.
HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.
JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.
iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
Smart Valor AG is a blockchain-based fintech company based in Zug, Switzerland, established in 2017. It provides a comprehensive digital asset platform that facilitates the issuance and distribution of investment solutions and banking services. The company operates a digital asset exchange and offers asset management services, making it the first full-service digital asset provider in Switzerland and Liechtenstein. Smart Valor connects banks and fintechs to a decentralized network of investors, enabling access to tokenized and liquid investments across various asset classes, including real estate, currencies, and art. Additionally, it offers a white-label software-as-a-service solution that supports financial institutions with tools for compliance, performance tracking, and customer verification. The company has received recognition for its innovative approach, including an award from the Swiss governmental innovation agency Innosuisse.
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Athelas, Inc. is a healthcare company based in Mountain View, California, that specializes in developing and manufacturing in-home blood analysis devices aimed at diagnosing infections, inflammations, and malignancies. Founded in 2002, Athelas has created a portable optical unit that analyzes blood samples from a single drop, providing diagnostic reports to monitor the immune system. The company's FDA-cleared device is designed to help chronically ill patients manage their health at home, offering additional monitoring for blood pressure, weight, glucose levels, and medication adherence. This technology enables patients to monitor their immunity and assists healthcare providers in the early detection of conditions such as leukemia and other inflammatory diseases. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.
MESA Imaging specializes in the development and production of 3D time-of-flight cameras designed to capture full 3D images at video frame rates. The company utilizes the Time-of-Flight (TOF) principle and incorporates innovative technologies such as silo pixel architecture and the SR4000 sensor chip, which enhance distance measurement capabilities. MESA Imaging supplies its advanced camera systems to various industries, including video gaming, machine vision, automotive, and robotics, thereby contributing to the enhancement of image-related applications.
Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
PicoDRILL SA is a private company based in Lausanne, Switzerland, specializing in micromachining techniques for creating hole structures in glass and dielectric materials. The company has developed a proprietary process known as Electrothermal Self-focusing, which enables the controlled heating and evaporation of precisely defined volumes in various substrates, including glass, ceramics, silica, and sapphire. This innovative technology addresses drilling needs within the nanotechnology sector, providing advanced solutions for its partners and customers.
Lambda Health System is a spin-off of the University of Applied Sciences of Canton de Vaud, focusing on development, production and commercialization of a rehabilitation robot for the lower limbs : LAMBDA. The LAMBDA is a cost-effective and easy to use robot which answers to the current needs of therapists. It offers various therapies usually contained in several devices with totally customizable parameters.
Advanon AG is an online financial services platform based in Zurich, Switzerland, focused on connecting small and medium-sized enterprises (SMEs) with investors. Established in 2015, the platform specializes in invoice financing, allowing SMEs to pre-finance their outstanding invoices. This service enables businesses to access liquidity more quickly, avoiding the lengthy wait times of 30 to 120 days for customer payments. Advanon operates as an authorized financial intermediary under Swiss regulations, ensuring compliance with the Anti Money Laundering Act. By facilitating flexible financing options with transparent pricing, Advanon aims to support the growth and cash flow stability of SMEs.
Flytrex is the largest drone-based food delivery service in the United States, primarily operating in North Carolina and Texas. The company has successfully fulfilled over 120,000 orders for various partners, including notable chains such as Little Caesars, Papa John's, and El Pollo Loco. Flytrex's service is designed to offer rapid delivery, reducing costs from $10 to $1 per package and cutting delivery times from 20 minutes to under 5. With a strong customer retention rate of 45% after two years and a household penetration of 70% within its service range, the company has garnered significant customer satisfaction, reflected in its high Net Promoter Score of 75. Flytrex employs advanced automated drone technology operated via a cloud-based control system, facilitating efficient deliveries even to hard-to-reach areas while minimizing operational expenses for retailers and delivery companies.
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Inositec is a biotech company focused on developing innovative treatments for soft tissue calcification disorders through its proprietary Inositune platform, which utilizes inositol phosphate (IP6) analogs. Founded in 2015 as a spin-off from ETH Zurich, Inositec specializes in the therapeutic engineering of small molecules by selectively modifying phosphate groups on inositol phosphates. This approach allows the creation of compounds with improved drug-like properties tailored for various therapeutic applications, particularly in addressing vascular and renal calcification disorders, including rare conditions. Through its research and development efforts, Inositec aims to provide effective treatment options for patients suffering from these disorders.
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Equippo.com is a commercial equipment company that sells and buys used equipment for the construction industry. They bring together select manufacturers, dealers, leasing companies, and other trusted sellers of heavy equipment with buyers from all over the world, including markets like South America, Russia, and Poland. It operates an online marketplace for used construction equipment. They are very proud of their most important and unique technological innovation - the Equippo final price calculation engine makes it even easier to deal internationally: tariffs, transport, and logistics specific to your region are already included in the price displayed. Equippo.com was founded in 2014 and is headquartered in Zug, Switzerland, Equippo’s dedicated team is as international as its mission; buyers and sellers can speak with salespeople in more than nine languages.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.
JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.
L.E.S.S. SA, founded in 2012 and based in Renens, Switzerland, specializes in the design and development of ultra-bright and ultra-thin lighting solutions. The company offers a range of products, including inspection lighting for microscopy and workbench applications, as well as automotive lighting systems. L.E.S.S. focuses on providing high and low angle, and shadowless illumination lighting systems suitable for various sectors, including automotive, machine vision, watchmaking, micromechanics, electronics, and medical applications. The company's innovative approach aims to deliver intense and uniform lighting within a compact form factor.
UniKey Technologies offers a mobile platform to replace keys, codes, and passwords by turning a smartphone into a universal electronic key. It develops and offers a “touch-to-open” technology, through which a smartphone can stay in a pocket or purse to keep hands free; delivers patent-pending intelligence that detects whether an authorized user is inside or outside of the home or building before granting access to help prevent unauthorized entry; and provides multiple levels of security. The company partners with lock manufactures, including Kwikset and Weiser to create smart locks such as Kevo. Its cloud-based lock management solution enables multifamily properties to manage multiple locks for each unit. It brings leading smart lock and access control technology to address the needs of small and large commercial businesses. UniKey’s eKey systems, paired with its partners’ locks for hospitality, enable complete key management. UniKey Technologies was founded in 2010 by Phil Dumas and is based in Florida, United States.
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Sonic Emotion AG is a Swiss company specializing in innovative audio solutions that deliver immersive 3D sound experiences. Founded in 2002 and headquartered in Zurich, with research facilities in France and sales offices across Asia, Sonic Emotion offers advanced audio technologies suitable for various environments, including 3D cinemas, events, museums, and theme parks. The company's flagship product, Absolute 3D sound technology, enables natural sound reproduction using a compact system that can operate with minimal channels, making it versatile for different applications. Additionally, Sonic Emotion provides audio simulation and OEM licensing solutions, as well as Headquake, a sound enhancement application for Apple devices. The company's focus on creating engaging audio experiences positions it as a leader in the field of sound technology.
Edimer Pharmaceuticals focuses on developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as insufficient sweat glands, impaired temperature regulation, respiratory difficulties, and abnormal hair and tooth development. The company aims to enhance the health and quality of life for individuals affected by this orphan disease. Edimer is supported by a team of experienced biotechnology professionals and a network of esteemed clinical and scientific advisors, all committed to advancing drug development for XLHED. Through its innovative approach, Edimer seeks to provide significant and lasting improvements in the management of this condition for future generations.
JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.
windeln.de, together with its subsidiaries, operates as an online retailer of products for babies, toddlers, children, and young mothers in Germany, Austria, Switzerland, the Czech Republic, Spain, and China. It operates through German Shop, International Shops, and Shopping Clubs segments. The company offers a range of products, including diapers, baby food, drugstore products, clothes, toys, strollers, child car seats, baby monitors, and children’s furniture.
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.
SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.
JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.
Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.
SilentSoft, established in 2000, specializes in Machine To Machine (M2M) technology and operates as a telemetry company. The firm has developed a comprehensive range of technologies and processes designed for the effective operation of M2M networks. SilentSoft collaborates with industrial clients to deploy and manage their M2M networks, focusing on solutions for monitoring tanks and meters. By connecting these devices, the company facilitates real-time communication and data exchange, helping clients optimize operations, reduce emergency deliveries, and decrease fuel consumption and carbon emissions.
CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Edimer Pharmaceuticals focuses on developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as insufficient sweat glands, impaired temperature regulation, respiratory difficulties, and abnormal hair and tooth development. The company aims to enhance the health and quality of life for individuals affected by this orphan disease. Edimer is supported by a team of experienced biotechnology professionals and a network of esteemed clinical and scientific advisors, all committed to advancing drug development for XLHED. Through its innovative approach, Edimer seeks to provide significant and lasting improvements in the management of this condition for future generations.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.
Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.
Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.